Drugs / IGM-2644
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05908396 | Aug 2023 → Feb 2024 | plasma cell myeloma | IGM Biosciences, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IGM-2644 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05908396 ↗ |
| Action | Deplete | “to selectively target and kill myeloma cancer cells” NCT05908396 ↗ |
| Route | Intravenous | “IGM-2644 will be administered intravenously (IV).” NCT05908396 ↗ |
| Target | CD38 | “IGM-2644 is designed to bind to CD38” NCT05908396 ↗ |